Assessment of the Potential of CDK2 Inhibitor NU6140 to Influence the Expression of Pluripotency Markers NANOG, OCT4, and SOX2 in 2102Ep and H9 Cells

Figure 3

CDK2 inhibitor NU6140 accumulates hES and hEC cells in the G2 phase and nocodazole accumulates cells in the G2/M phase of the cell cycle. Changes in the cell cycle distribution of hES (H9 cells) and hEC (2102Ep cells) cells treated with NU6140, nocodazole, DMSO, or maintenance medium (untreated cells). (a) Distribution of cells within different cell cycle phases. Ethanol fixed and propidium iodide stained cells were analysed by flow cytometry and cell cycle analysis was performed by using ModFit software. (b) Histone 3 phosphorylation at Serine 10 was done using flow cytometric analysis. Results are representative of two independent experiments and shown as density plots. (c) Mean fluorescence intensity (MFI) of CDK2+H3P+ (white empty bar) and CDK2+H3P− (black filled bar) populations as gated in the last density plot (CDK2 expression versus H3 phosphorylation). Results are shown as mean ± SEM ().

(a)

(b)

(c)